U.S. market Open. Closes in 5 hours 9 minutes

BBLG | Bone Biologics Corporation Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.2100 - 1.2918
52 Week Range 0.8000 - 10.56
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 7,260
Average Volume 3,044,195
Shares Outstanding 2,463,534
Market Cap 2,980,876
Sector Healthcare
Industry Medical - Devices
IPO Date 2021-10-13
Valuation
Profitability
Growth
Health
P/E Ratio -0.83
Forward P/E Ratio N/A
EPS -1.46
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 2
Country USA
Website BBLG
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
*Chart delayed
Analyzing fundamentals for BBLG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see BBLG Fundamentals page.

Watching at BBLG technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on BBLG Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙